Belzutifan, the first-in-class HIF-2α inhibitor, was approved by the US Food and Drug Administration (FDA) in 2021 for the treatment of RCC with germline VHL mutations (VHL disease). This evidence concerns the gene VHL and renal cell carcinoma.